Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.

Bioassay 130

Bioassay RNA Development Drugs 130

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.

Genome 52

Genome Genomics RNA Genome Project 52

XTalks

JANUARY 21, 2025

The Onclarity HPV reagent pack extraction combo. ColoSense is a laboratory test that detects eight different RNA biomarkers and trace amounts of hemoglobin (as a measure of blood) in human stool that is not visible to the naked eye (fecal occult blood). Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

XTalks

AUGUST 18, 2020

An important feature of the test that contributes to its reduced cost is the fact that sample processing does not require a separate nucleic acid (RNA) extraction step. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genomics 90

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Nanoparticles Contract Manufacturing.

Marketing 52

Marketing Gene Sequencing DNA Genomics 52

pharmaphorum

FEBRUARY 3, 2021

This can be partly attributed to the reagents and delivery modalities that were available at the time of the trial start in 2016, leading to low editing efficiency at the target loci. However, the number of CAR-T cells with all four genes correctly targeted was low.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries. Players Engaged in the Domain.

Genetics 52

Genetics DNA RNA Reagent 52